レオクラン has raised its ordinary profit forecast for the fiscal year ending September 2026 from the previous forecast of ¥610 million to ¥820 million. It has also raised its full-year forecast for the current fiscal year, with the expected return to profitability in the second half now larger than previously anticipated.
レオクラン announced after the close of trading on 14 September that it had raised its consolidated ordinary profit forecast for the fiscal year ending September 2026 from the previous forecast of ¥610 million to ¥820 million. With ordinary profit of ¥300 million recorded in the previous fiscal year, the company expects an increase of approximately 34.4%. The revision reflects upside in revenue and profit at each stage, as the company captured healthcare institutions’ replacement demand, including stronger-than-expected sales of medical equipment in bundled transactions and medical information systems such as electronic medical records.
The outlook for the second half has also improved under the new plan. Consolidated ordinary income for April-September is now expected to be a profit of ¥310 million, up from the previous forecast of a ¥100 million profit and turning around from a ¥200 million loss in the same period of the previous year. The company said that the business of the ファスキア Group is also contributing.
Key figures in the new full-year plan include second-half revenue of ¥23,720 million, operating profit of ¥364 million, ordinary profit of ¥313 million, net profit of ¥165 million, revised EPS of ¥27.9 and a revised dividend per share of ¥17. The current fiscal year’s full-year forecast has been significantly raised across the board, including revenue from ¥44,500 million to ¥48,000 million and ordinary profit from ¥610 million to ¥820 million.